U.S. flag An official website of the United States government
  1. Home
  2. News & Events
  3. FDA Meetings, Conferences and Workshops
  4. FDA Oncology Center of Excellence: Conversation on Cancer - Latino Community: Achieving Equity in Cancer Clinical Trials - 09/24/2020 - 09/24/2020
  1. FDA Meetings, Conferences and Workshops

Webcast

Event Title
FDA Oncology Center of Excellence: Conversation on Cancer - Latino Community: Achieving Equity in Cancer Clinical Trials
September 24, 2020


Date:
September 24, 2020
Time:
1:00 PM - 2:30 PM ET
Organized By:

Twitter: #OCEProjectCommunity

Sponsored by the U.S. Food & Drug Administration (FDA)

Speakers:

Pam Balcazar, MS—Cancer Patient Caretaker/Senior Regulatory Project Manager, Office of Oncologic Diseases, FDA

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE—Executive Director/Professor of Medicine & Biochemistry, University of Puerto Rico Comprehensive Cancer

Ysabel Duron—President/Executive Director, The Latino Cancer Institute

Jorge Nieva, MD—Associate Professor of Clinical Medicine, University of Southern California

Amelie Ramirez, DrPH, MPH—Chair and Professor, University of Texas Health Science Center of San Antonio/Associate Director, Mays Cancer Center Community Outreach and Engagement

Georgia Sadler, BSN, MBA, PhD—Emeritus Professor, Department of Surgery at the University of California San Diego School of Medicine

Registration:

Registration Link

Background:

Latinos are underrepresented in cancer clinical trials and genomic databases that capture information leading to the development of cancer treatments. What are actions the oncology community can take to improve recruitment and inclusion of Latino subgroups in cancer clinical trials?

Please join FDA's Oncology Center of Excellence for a dynamic panel discussion about barriers and opportunities to achieving equity in cancer clinical trials by increasing participation in the Latino community.

Webcast Information:

FDA provided a free-of-charge, live webcast of this workshop.

Contact:

For additional information, please send an email to: OCE-Engagement@fda.hhs.gov

 

Back to Top